BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

University of Pennsylvania researchers have found a promising new treatment for periodontitis using a component of the immune system called complement, according to a new study in the Journal of ...

India has taken a significant step forward in the field of immunology with the launch of its first dedicated complement testing laboratory, designed to improve the diagnosis of complex autoimmune and ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that ...

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024; Potential to be First Approved Treatment for GBS Patients in the U.S. Clinical Proof-of-Concept Study of ...

Dr. Lal PathLabs (DLPL), one of India’s leading diagnostic networks has launched India’s first dedicated Complement Testing Laboratory, strengthening its position as the country’s leading hub for ...

Dianthus Therapeutics, Inc.'s DNTH103 is being evaluated in the phase 2 MaGic trial, which is targeting patients with generalized myasthenia gravis. The global myasthenia gravis treatment market size ...

-- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the ...

Researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery. Our immune system is armed with an array of defenses designed to detect and ...